{"generic":"Cobicistat","drugs":["Cobicistat","Tybost"],"mono":{"0":{"id":"jy9ms0","title":"Generic Names","mono":"Cobicistat"},"1":{"id":"jy9ms1","title":"Dosing and Indications","sub":[{"id":"jy9ms1b4","title":"Adult Dosing","mono":"<ul><li>Before initiating cobicistat, assess estimated CrCl. Cobicistat inhibits tubular secretion of creatinine and decreases estimated CrCl but does not affect actual glomerular filtration. If coadministering cobicistat with tenofovir disoproxil fumarate, assess estimated CrCl, urine glucose, and urine protein before initiating treatment.<\/li><li><b>HIV infection, To increase systemic exposure of once daily atazanavir or darunavir:<\/b> 150 mg ORALLY once daily coadministered with either atazanavir 300 mg ORALLY once daily or darunavir 800 mg ORALLY once daily in patients with no darunavir resistance-associated substitutions<\/li><\/ul>"},{"id":"jy9ms1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients younger than 18 years "},{"id":"jy9ms1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> No dose adjustment needed<\/li><li><b>renal impairment, estimated CrCl less than 70 mL\/min:<\/b> Concomitant use with tenofovir not recommended.<\/li><li><b>hepatic impairment, mild (Child-Pugh class A) to moderate (Child-Pugh class B):<\/b> No dose adjustment needed<\/li><\/ul>"},{"id":"jy9ms1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection, To increase systemic exposure of once daily atazanavir or darunavir<br\/>"}]},"3":{"id":"jy9ms3","title":"Contraindications\/Warnings","sub":[{"id":"jy9ms3b9","title":"Contraindications","mono":"<ul><li>coadministration with alfuzosin<\/li><li>coadministration with cisapride<\/li><li>coadministration with dronedarone<\/li><li>coadministration with ergot derivatives (ie, dihydroergotamine, ergotamine, methylergonovine)<\/li><li>coadministration with HMG-CoA reductase inhibitors (ie, lovastatin, simvastatin)<\/li><li>coadministration with indinavir and atazanavir<\/li><li>coadministration with irinotecan and atazanavir<\/li><li>coadministration with nevirapine and atazanavir<\/li><li>coadministration with pimozide<\/li><li>coadministration with rifampin<\/li><li>coadministration with sedative\/hypnotics (ie, triazolam, orally-administered midazolam)<\/li><li>coadministration with sildenafil (for pulmonary arterial hypertension)<\/li><li>coadministration with St. John's wort<\/li><\/ul>"},{"id":"jy9ms3b10","title":"Precautions","mono":"<ul><li>Renal:<\/li><li>-- increased serum creatinine and decreased creatinine clearance, without affecting actual renal glomerular function, may occur; monitoring recommended<\/li><li>-- renal impairment has been reported when coadministered with tenofovir disoproxil fumarate<\/li><li>Concomitant Use:<\/li><li>-- avoid use with rivaroxaban<\/li><li>-- avoid use with tadalafil when initiating cobicistat in combination with atazanavir or darunavir<\/li><li>-- use with atazanavir in combination with efavirenz in treatment-experienced patients not recommended<\/li><li>-- use with avanafil not recommended<\/li><li>-- use with boceprevir, simeprevir, or telaprevir not recommended<\/li><li>-- use with colchicine in patients with renal or hepatic impairment not recommended<\/li><li>-- use with darunavir 600 mg twice daily not recommended<\/li><li>-- use with darunavir in combination with efavirenz or nevirapine not recommended<\/li><li>-- use with etravirine not recommended<\/li><li>-- use with HIV-1 protease inhibitors other than atazanavir or darunavir (eg, fosamprenavir, saquinavir, or tipranavir) not recommended<\/li><li>-- use with lopinavir not recommended<\/li><li>-- use with more than 1 antiretroviral requiring pharmacokinetic enhancement (ie, two protease inhibitors or elvitegravir in combination with a protease inhibitor) not recommended<\/li><li>-- use with proton-pump inhibitors in treatment-experienced patients not recommended<\/li><li>-- use with ritonavir not recommended<\/li><li>-- use with salmeterol not recommended<\/li><li>-- use with cobicistat combination products (eg, elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate) not recommended<\/li><li>-- use with tenofovir disoproxil fumarate in combination with current or recent use of a nephrotoxic agent not recommended<\/li><li>-- use with tenofovir disoproxil fumarate in patients with an estimated CrCl below 70 mL\/min not recommended<\/li><li>-- use with voriconazole not recommended<\/li><\/ul>"},{"id":"jy9ms3b11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"jy9ms3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jy9ms4","title":"Drug Interactions","sub":[{"id":"jy9ms4b13","title":"Contraindicated","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Colchicine (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergonovine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Eszopiclone (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Methylergonovine (theoretical)<\/li><li>Midazolam (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Riociguat (theoretical)<\/li><li>Romidepsin (probable)<\/li><li>Sildenafil (theoretical)<\/li><li>Silodosin (probable)<\/li><li>Simvastatin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><\/ul>"},{"id":"jy9ms4b14","title":"Major","mono":"<ul><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Alprazolam (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amobarbital (theoretical)<\/li><li>Amprenavir (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Armodafinil (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Avanafil (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Buspirone (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Cabazitaxel (established)<\/li><li>Cabozantinib (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Cladribine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clobazam (theoretical)<\/li><li>Clofarabine (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clozapine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dactinomycin (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Daunorubicin (theoretical)<\/li><li>Delamanid (probable)<\/li><li>Delavirdine (probable)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diazepam (theoretical)<\/li><li>Digoxin (established)<\/li><li>Disopyramide (theoretical)<\/li><li>Docetaxel (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Ethosuximide (theoretical)<\/li><li>Etoposide (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Fosamprenavir (probable)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lidocaine (theoretical)<\/li><li>Lopinavir (probable)<\/li><li>Losartan (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Macitentan (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Mephobarbital (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Mexiletine (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mitoxantrone (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Montelukast (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Netupitant (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxaliplatin (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Palbociclib (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Prazosin (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Retapamulin (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Ritonavir (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Roflumilast (theoretical)<\/li><li>Rosuvastatin (established)<\/li><li>Rufinamide (theoretical)<\/li><li>Ruxolitinib (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saquinavir (probable)<\/li><li>Saxagliptin (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Sumatriptan (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tadalafil (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (probable)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Thiopental (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (probable)<\/li><li>Topiramate (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinblastine (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinorelbine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"},{"id":"jy9ms4b15","title":"Moderate","mono":"<ul><li>Atazanavir (probable)<\/li><li>Darunavir (probable)<\/li><li>Indinavir (probable)<\/li><li>Nelfinavir (probable)<\/li><\/ul>"}]},"5":{"id":"jy9ms5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (12%)<\/li><li><b>Hepatic:<\/b>Jaundice (13%)<\/li><li><b>Ophthalmic:<\/b>Scleral icterus (15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Rash (5% (grades 2 to 4))<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis (less than 2%)<\/li><li><b>Renal:<\/b>Acquired Fanconi syndrome (less than 2%), Acute renal failure, Kidney disease (less than 2%)<\/li><\/ul>"},"6":{"id":"jy9ms6","title":"Drug Name Info","sub":{"0":{"id":"jy9ms6b17","title":"US Trade Names","mono":"Tybost<br\/>"},"2":{"id":"jy9ms6b19","title":"Class","mono":"Anti-Infective Agent<br\/>"},"3":{"id":"jy9ms6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy9ms6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy9ms7","title":"Mechanism Of Action","mono":"Cobicistat, an inhibitor of CYP3A subfamily enzymes, enhances systemic exposure to CYP3A substrates that have limited oral bioavailability and a short half-life due to CYP3A-mediated metabolism, such as atazanavir and darunavir.<br\/>"},"8":{"id":"jy9ms8","title":"Pharmacokinetics","sub":[{"id":"jy9ms8b23","title":"Absorption","mono":"Tmax, oral: approximately 3.5 hours <br\/>"},{"id":"jy9ms8b24","title":"Distribution","mono":"Protein binding: 97% to 98% <br\/>"},{"id":"jy9ms8b25","title":"Metabolism","mono":"<ul><li>Hepatic: extensive<\/li><li>inhibitor of CYP3A (strong), CYP2D6 (weak), p-glycoprotein (P-gp), efflux transporter Breast Cancer Resistant Protein (BCRP), OATP1B1 transporter, and OATP1B3 transporter<\/li><li>substrate of CYP3A, CYP2D6 (minor)<\/li><\/ul>"},{"id":"jy9ms8b26","title":"Excretion","mono":"<ul><li>Fecal: 86.2% (primarily unchanged)<\/li><li>Renal: 8.2% (primarily unchanged)<\/li><li>Dialyzable: unlikely via hemodialysis or peritoneal dialysis<\/li><\/ul>"},{"id":"jy9ms8b27","title":"Elimination Half Life","mono":"3 to 4 hours <br\/>"}]},"9":{"id":"jy9ms9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>must be coadministered at the same time with once-daily atazanavir or darunavir<\/li><li>administer once daily with food<\/li><\/ul>"},"10":{"id":"jy9ms10","title":"Monitoring","mono":"<ul><li>Viral load: at baseline and with modification of antiretroviral (ARV) treatment, at 2 to 8 weeks; then every 4 to 8 weeks until values are below the limit of detection (less than 200 copies\/mL), then every 3 to 4 months; monitoring may be extended to every 6 months for patients who are immunologically stable, adherent, and with suppressed viral loads for more than 2 years<\/li><li>CD4 cell counts: at baseline and with modification of ARV treatment, then every 3 to 6 months during the at least the first 2 years of treatment and if the CD4 counts are below 300 cells\/mm(3) or viremia develops; after 2 years monitoring may be extended to every 12 months for patients who are clinically stable with suppressed viral loads<\/li><li>Hepatitis B screening: baseline and with modification of ARV treatment; may repeat screening if hepatitis B surface antigen or antibody are negative at baseline.<\/li><li>ALT, AST, and total bilirubin; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>Basic chemistry, including serum sodium, potassium, bicarbonate, chloride, BUN, and creatinine; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>CBC with a differential; at baseline and with modification of ARV treatment, then every 3 to 6 months<\/li><li>Fasting blood glucose or HbA1c; at baseline and with modification of ARV treatment, then every 3 to 6 months with abnormal values or 12 months with normal values<\/li><li>Fasting lipid profile; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 6 to 12 months<\/li><li>Urinalysis; at baseline or modification of ARV treatment, then annually<\/li><li>CrCl; before treatment initiation<\/li><li>CrCl, urine glucose, and urine protein; at baseline and routinely during therapy with coadministration of tenofovir disoproxil fumarate<\/li><li>serum phosphorus; with coadministration of tenofovir disoproxil fumarate in patients with current or potential renal impairment<\/li><\/ul>"},"11":{"id":"jy9ms11","title":"How Supplied","mono":"<b>Tybost<\/b><br\/>Oral Tablet: 150 MG<br\/>"},"13":{"id":"jy9ms13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include nausea, ocular icterus, or jaundice.<\/li><li>Counsel patient to take tablet with food and at the same time with second drug.<\/li><li>Instruct patient to take a missed dose as soon as possible, but if next dose is in less than 12 hours, skip the missed dose.<\/li><\/ul>"}}}